Isracann Biosciences Net Income vs. Price To Book
Based on Isracann Biosciences' profitability indicators, Isracann Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in January. Profitability indicators assess Isracann Biosciences' ability to earn profits and add value for shareholders.
Check out Risk vs Return Analysis.
For Isracann Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Isracann Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Isracann Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Isracann Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Isracann Biosciences over time as well as its relative position and ranking within its peers.
Isracann |
Isracann Biosciences Price To Book vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Isracann Biosciences's current stock value. Our valuation model uses many indicators to compare Isracann Biosciences value to that of its competitors to determine the firm's financial worth. Isracann Biosciences is rated below average in net income category among its peers. It is rated second overall in price to book category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Isracann Biosciences' earnings, one of the primary drivers of an investment's value.Isracann Price To Book vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Isracann Biosciences |
| = | (4.69 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Isracann Biosciences |
| = | 9.57 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Isracann Price To Book Comparison
Isracann Biosciences is currently under evaluation in price to book category among its peers.
Isracann Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Isracann Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Isracann Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Isracann Biosciences' change in net profit over the period of time. It can combine multiple indicators of Isracann Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Isracann Biosciences Inc., together with its subsidiaries, cultivates and distributes medical cannabis in Israel. Isracann Biosciences Inc. was founded in 2010 and is headquartered in Vancouver, Canada. Isracann Biosciences is traded on OTC Exchange in the United States.
Isracann Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Isracann Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Isracann Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Isracann Biosciences' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Isracann Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
All Next | Launch Module |
Use Investing Themes to Complement your Isracann Biosciences position
In addition to having Isracann Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Thematic Idea Now
Healthcare
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Healthcare theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Theme or any other thematic opportunities.
View All Next | Launch |
Other Information on Investing in Isracann Pink Sheet
To fully project Isracann Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Isracann Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Isracann Biosciences' income statement, its balance sheet, and the statement of cash flows.